CRL logo

CHARLES RIVER LABORATORIES

CRLNYSE
πŸ† #567 by market capEarnings Nov 4 Β· PreUS Equity
$373.98β–² $15.14 (+4.22%)
πŸŒ™ After hours$375.00β–² 0.27%Regular close Β· extended-hours price shown
πŸ””
Track CRL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 4.2%
7dβ–² 10.0%
14dβ–² 22.0%
30dβ–² 26.3%
ytdβ–² 87.3%
1yβ–² 107.6%
🏦Market Cap
$17.85B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-0.7%
Declining
πŸ“ŠGross Margin
34.6%
Moderate
πŸ’΅FCF Margin
9.6%
Moderate
βš–οΈP/S Ratio
4.4x
Fair
Otter Score
68
Fair

Trading Snapshot

Day Range
$360.01 – $378.23
52-Week Range
$146.20 – $359.89
Volume (shares)
1,299,353
Avg Volume (shares)
β€”
Shares Outstanding
47.7M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$4.02B
Last Q Revenue
$1.00B
P/E Ratio
β€”
P/S Ratio
4.4x
EPS (TTM)
$-4.85
Dividend Yield
β€”
Dilution (1yr)
βˆ’3.8%
CRL logo

CHARLES RIVER LABORATORIES

CRL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4.0Bβ–Ό βˆ’0.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
30.5%β–Ό βˆ’7.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$508Mβ–² +123.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$518Mβ–² +3.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
49.2Mβ–Ό βˆ’3.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$2.9Bβ–Ό βˆ’$322M YoY
StockOtter Β· stockotter.space

About CHARLES RIVER LABORATORIES

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Ratings

β“˜
Consensus
Buy
23 analysts
Strong Buy7
Buy11
Hold5
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Zacks Investment ResearchΒ·15h ago

Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking AlphaΒ·23h ago

Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts

Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds into Royal Caribbean

Business WireΒ·1d ago

Charles River Leverages Virtual Control Groups in GLP Studies

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.

Defense WorldΒ·1d ago

Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 24,042 Shares of Company Stock

Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) Director James Foster sold 24,042 shares of the company's stock in a transaction dated Thursday, October 22nd. The shares were sold at an avera

Defense WorldΒ·1d ago

8,883 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Evergreen Capital Management LLC

Evergreen Capital Management LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE: CRL) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commissio

Seeking AlphaΒ·2d ago

Ariel Fund Q3 2026 Leaders And Laggards

ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology customers. Bio-Rad's sha